Sandoz Collaborates With Evotec For AI-Powered Biosimilars

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Sandoz, Just-Evotec Biologics have announced a collaboration to develop and manufacture multiple biosimilars. In the said agreement, Sandoz will get access to an AI-led technology platform that goes on to deliver completely integrated development of drug substances as well as consistent manufacturing. This will help in supporting Sandoz’s pipeline elevation to 24 biosimilar assets.

Utilising artificial intelligence so as to manufacture biosimilars

Because of the strategic collaboration, both parties happen to be sharing a commitment to use disruptive technologies with low operational costs in order to deliver biosimilars at a scale of high quality for patients across the world, as per Richard Saynor, the CEO of Sandoz.

By way of intensifying as well as shrinking the footprint of their manufacturing facility with the help of these technologies, the cost of production can be lowered, opined Radal Bass, the executive vice president of process design and biotherapeutic operations at Just-Evotec Biologics.

Consistent manufacturing of biologics

Within this collaboration, Sandoz happens to have the option to make use of Evotec Biologics’ advanced and consistent manufacturing process.

The state-of-the-art manufacturing and drug development technology goes on to deliver elevated quality as well as productivity when it comes to the production of biologics.

As per Richard Saynor, the agreement goes on to offer multiple capabilities to help in the strategic expansion of the pipeline by way of novel assets and to begin the transitioning immediately of the biosimilar pipeline being used earlier, thereby making sure of continuity when it comes to development as well as manufacturing while the planned separation from Novartis is finalised by Sandoz.

Notably, the development of biosimilars is expected to ramp up in the next 12–18 months.

Latest stories

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back